Other
Autonomic Nervous System
0
Pipeline Programs↗
1
Active Trials↗
1
Companies Involved↗
Autonomic Nervous System is an early-stage landscape with 0 programs across 1 company. The most active players are GSK.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
11
clinical trials
Completed8 · 73%
Unknown status2 · 18%
Recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
Completed·—·Phase 4·NCT02048072·33 enrolled
Comparison of the Effects of Dexmedetomidine and Propofol on the Cardiovascular Autonomic Nervous System During Spinal Anesthesia
Completed·—·N/A·NCT04142502·60 enrolled
Autonomic Nervous System Reactivity of the Newborn After a Nociceptive Stress: Interest of Sucrose and Non-nutritive Sucking
Completed·—·Phase 3·NCT02374281·180 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)